MYRIAD GENETICS INC (MYGN)
D
Pipeline Grade
Financial Position (from SEC Filings)
$126.0M
Cash & Equivalents
$15.7M
Quarterly Burn Rate
24 mo
Est. Cash Runway
$551M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (5)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07052266 | Trial of Combined Obstetric Carrier Screening and Hereditary Cancer Screening | OTHER | Recruiting | 550 |
| NCT05457257 | Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Pr... | PHASE4 | Active Not Recruiting | 43 |
| NCT02655016 | A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response ... | PHASE3 | Active Not Recruiting | 733 |
| NCT05642780 | SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors | PHASE2 | Active Not Recruiting | 240 |
| NCT04150042 | SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells | PHASE1 | Recruiting | 24 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.